Rebound Tumour Progression After the Cessation of Bevacizumab Therapy in Patients with Recurrent High-grade Glioma

Overview

Journal J Neurooncol

Publisher Springer

Date 2010 Feb 13

PMID 20151176

Citations 38

Authors

Richard M Zuniga

Roy Torcuator

Rajan Jain

John Anderson

Thomas Doyle

Lonni Schultz

Tom Mikkelsen

Affiliations

Soon will be listed here.

Abstract

After withdrawal of bevacizumab in patients with recurrent high-grade glioma, we have observed a rapid tumour re-growth or "rebound" radiographic phenomenon with accelerated clinical decline. We retrospectively reviewed 11 patients treated at the Henry Ford Hermelin Brain Tumor Center with recurrent high-grade glioma who demonstrated a rebound progression pattern after the discontinuation of bevacizumab. The original tumour area-of-enhancement increased by a mean of 158%, when compared to the rebound magnetic resonance imaging. After rebound, no patients (0/8) showed a response to next-line treatments that did not include bevacizumab. The median survival of those re-treated with bevacizumab was 149 and 32 days for those who received other regimens. Abrupt discontinuation of bevacizumab after recurrence often leads to a dramatic rebound phenomenon and rapid clinical decline. Slow tapering of the bevacizumab dose after tumour progression may prevent this from occurring and improve responsiveness to next-line therapies.

Citing Articles

Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.

Sener U, Islam M, Webb M, Kizilbash S Neurooncol Adv. 2024; 6(1):vdae039.

PMID: 38596714 PMC: 11003534. DOI: 10.1093/noajnl/vdae039.

Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.

Webb M, Neth B, Webb L, Van Gompel J, Link M, Neff B Neurooncol Adv. 2023; 5(1):vdad123.

PMID: 37841698 PMC: 10576512. DOI: 10.1093/noajnl/vdad123.

An Observatory for the Oncogene: A Guide for Targeted Therapies.

Altintas D, Comoglio P Cancers (Basel). 2023; 15(18).

PMID: 37760640 PMC: 10526818. DOI: 10.3390/cancers15184672.

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

Ghezelayagh T, Wu E, Barber E, Dao M, Zsiros E, Urban R Eur J Gynaecol Oncol. 2023; 44(1):17-25.

PMID: 36874058 PMC: 9980410. DOI: 10.22514/ejgo.2023.002.

An mTOR feedback loop mediates the 'flare' ('rebound') response to MET tyrosine kinase inhibition.

Altintas D, Cerqua M, De Laurentiis A, Trusolino L, Boccaccio C, Comoglio P Sci Rep. 2023; 13(1):1378.

PMID: 36697438 PMC: 9876934. DOI: 10.1038/s41598-023-28648-3.

References

Ferrara N . VEGF as a therapeutic target in cancer. Oncology. 2005; 69 Suppl 3:11-6. DOI: 10.1159/000088479. View

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. DOI: 10.1056/NEJMoa072113. View

Yang J, Haworth L, Sherry R, Hwu P, Schwartzentruber D, Topalian S . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-34. PMC: 2275324. DOI: 10.1056/NEJMoa021491. View

Zuniga R, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S . Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2008; 91(3):329-36. DOI: 10.1007/s11060-008-9718-y. View

Mancuso M, Davis R, Norberg S, OBrien S, Sennino B, Nakahara T . Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006; 116(10):2610-21. PMC: 1578604. DOI: 10.1172/JCI24612. View

Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70(10):779-87. DOI: 10.1212/01.wnl.0000304121.57857.38. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

10.

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

11.

Pradeep C, Sunila E, Kuttan G . Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther. 2005; 4(4):315-21. DOI: 10.1177/1534735405282557. View

12.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

13.

Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O . Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008; 19(9):1659-61. DOI: 10.1093/annonc/mdn540. View

14.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

15.

Matsumoto Y, Freund K, Peiretti E, Cooney M, Ferrara D, Yannuzzi L . Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 2007; 27(4):426-31. DOI: 10.1097/IAE.0b013e31804a7af2. View

16.

Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T . Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008; 88(3):339-47. DOI: 10.1007/s11060-008-9573-x. View

17.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

18.

Kargiotis O, Rao J, Kyritsis A . Mechanisms of angiogenesis in gliomas. J Neurooncol. 2006; 78(3):281-93. DOI: 10.1007/s11060-005-9097-6. View